Sequent Scientific Limited has submitted the Exchange a copy Srutinizers report of Court Convened General Meeting held on August 30, 2025
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sequent Scientific Limited held a court-convened meeting of equity shareholders on August 30, 2025, via video conferencing to seek approval for a composite scheme of amalgamation involving 10 entities, including Symed Labs, Viyash Life Sciences, and Sequent Research. Out of 148,161 shareholders on record date, 61 public shareholders attended through VC, and voting was carried out via remote e-voting and e-voting at the meeting. A total of 188,838,066 votes (75.43% of outstanding shares) were polled, with 99.9952% voting in favour and only 9,125 votes (0.0048%) against. Public shareholders, who voted separately as required by SEBI rules, also approved the scheme with 99.984% in favour. The scrutinizer confirmed the resolution was passed by the requisite majority of three-fourths in value, meeting all legal thresholds.
This near-unanimous shareholder approval clears a major regulatory milestone for the proposed amalgamation, reducing execution risk. However, the scheme still requires final sanction from the NCLT before becoming effective, so shareholders should await the next update. The consolidation could streamline operations across the group but no immediate price catalyst is expected until NCLT approval is received.